R Squared’s Maravai LifeSciences MRVI Stock Holding History

R Squared’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$77.5K	Buy	27,394 +11,827	+76%	+$40.1K	0.04%	390
2025 Q4	$50.6K	Buy	+15,567	New	+$52.4K	0.02%	459

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R Squared's MRVI Position: Q1 2026 in Review

R Squared increased its Maravai LifeSciences (MRVI) stake by 76% in Q1 2026, buying an estimated $40.1K and bringing the position to 27,394 shares worth $77.5K. The position accounts for 0.04% of the portfolio, ranked #390.

R Squared first reported a position in MRVI in Q4 2025 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

R Squared held 27,394 shares of Maravai LifeSciences worth $77.5K as of Q1 2026.
R Squared bought 11,827 Maravai LifeSciences shares in Q1 2026, an estimated $40.1K.
Maravai LifeSciences made up 0.04% of R Squared's portfolio in Q1 2026, its #390 holding.
R Squared first reported a position in Maravai LifeSciences in Q4 2025 and has held it in 2 quarters since.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.